Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Niagen Bioscience, Inc.

Capitalization 392M 339M 306M 293M 534M 36.19B 549M 3.62B 1.44B 17.3B 1.47B 1.44B 62.32B P/E ratio 2026 *
18.1x
P/E ratio 2027 * 14.2x
Enterprise value 392M 339M 306M 293M 534M 36.19B 549M 3.62B 1.44B 17.3B 1.47B 1.44B 62.32B EV / Sales 2026 *
2.65x
EV / Sales 2027 * 2.28x
Free-Float
64.6%
Yield 2026 *
-
Yield 2027 * -
1 day-6.32%
1 week-1.01%
Current month-3.17%
1 month-4.31%
3 months-26.24%
6 months-49.17%
Current year-23.11%
1 week 4.82
Extreme 4.82
5.4
1 month 4.72
Extreme 4.725
5.78
Current year 4.72
Extreme 4.725
6.86
1 year 4.72
Extreme 4.725
14.69
3 years 1.25
Extreme 1.25
14.69
5 years 1.15
Extreme 1.15
14.69
10 years 1.15
Extreme 1.15
23.66
Manager TitleAgeSince
Chief Executive Officer 66 01/06/2018
Director of Finance/CFO 35 21/10/2024
Chief Tech/Sci/R&D Officer - 01/09/2014
Director TitleAgeSince
Chairman 57 22/06/2018
Director/Board Member 66 09/07/2015
Director/Board Member 65 27/03/2017
Change 5d. change 1-year change 3-years change Capi.($)
-6.32%-1.01%-38.10%+230.41% 392M
-1.39%-6.85%-8.31%-8.31% 44.08B
-2.12%-0.04%+21.65%+38.23% 33.16B
+1.46%+5.88%+18.52%+47.53% 30.96B
+0.38%-3.54%-6.49%-13.02% 28.8B
+0.74%-1.58%+156.08%+379.72% 19.74B
-5.41%-5.75%+56.22%+114.20% 13.96B
+2.34%+2.55%+46.60%+172.31% 13.56B
-0.75%-5.48%+25.26%-0.38% 12.88B
-1.15%-5.87%+126.43%+120.23% 12.35B
Average -1.22%-2.88%+39.79%+108.09% 20.99B
Weighted average by Cap. -0.62%-3.15%+33.86%+71.44%

Financials

2026 *2027 *
Net sales 148M 128M 115M 110M 201M 13.64B 207M 1.36B 544M 6.52B 555M 543M 23.49B 172M 148M 134M 128M 234M 15.84B 240M 1.58B 631M 7.57B 644M 631M 27.28B
Net income 22.46M 19.41M 17.52M 16.76M 30.55M 2.07B 31.41M 207M 82.57M 990M 84.29M 82.51M 3.57B 28.48M 24.61M 22.22M 21.25M 38.73M 2.63B 39.82M 263M 105M 1.26B 107M 105M 4.52B
Net Debt - -
Logo Niagen Bioscience, Inc.
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Employees
117
Date Price Change Volume
11/03/26 4.890 $ -6.32% 1,781,670
10/03/26 5.220 $ +2.15% 1,947,857
09/03/26 5.110 $ +0.99% 2,794,872
06/03/26 5.060 $ -0.78% 2,432,348
05/03/26 5.100 $ +3.24% 4,492,503
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.890USD
Average target price
13.60USD
Spread / Average Target
+178.12%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW